Mountain Valley MD Holdings Inc. (the “Company” or
“MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to
provide a general business update on its progress across its three
core lines of business:
- Nutraceuticals - novel innovations through the Company’s
Quicksome™ technology that are designed to improve the
administration and efficacy of nutraceutical health and wellness
products;
- Agriculture – the Company’s licensed Agrarius
agricultural plant signaling technology that is designed to
organically drive increases in crop yields and overall plant
health, while offering the potential to reduce fertilizer and
pesticide use where desired; and
- Husbandry Animals/Aquatic Species - the application of
solubilized drugs through the Company’s Quicksol™ technology that
is designed to positively impact the health of husbandry animals
and aquatic species.
"This past six months has been a truly transformative window for
MVMD and our extensive partner network as we see the
differentiation and positive reception of our technologies in the
marketplace,” stated Dennis Hancock, President & CEO of
Mountain Valley MD. “I am very proud of our team who is working
tirelessly during this pivotal phase in our journey, delivering
innovative products with unique value propositions, all while
supporting the scaling of our operations and expansion of our
strategic partnerships across a broad distribution territory.”
BUSINESS UPDATES
NUTRACEUTICALS
Quicksome™ Powered Products and Business Development
Progress
MVMD’s contracted manufacturing partner in the U.S. (“Lead
Manufacturer”) has completed the set-up and testing of equipment to
enable the proprietary production of nutraceutical applications for
MVMD’s Quicksome™ technology, including sublingual rapid dissolve
tablets and powders. The GMP manufacturing facility is now fully
operational and supporting Quicksome™ related business development
and manufacturing requirements.
The Lead Manufacturer has worked closely with the Company to
complete the initial product and production elements necessary to
support the MVMD’s current license agreement with Circadian
Wellness (“Circadian”) for mushroom-based nutraceutical products
embodying the Company’s proprietary Quicksome™ technology, as well
as for MVMD’s proprietary product line, “Mountains Of…”, and
additional business development projects with potential new
licensees.
The Company has completed product formulation work for Circadian
for its Eons branded product line-up, including sleep, energy,
immunity and most recently, an amanita mushroom product. Circadian
commenced sales of its mushroom-infused sublingual sleep product,
Eons Deeper Sleep, embodying MVMD’s technology in February 2024 on
its website eons.com, with the additional products deemed
“manufacturing ready” for Circadian to direct the Lead Manufacturer
in line with its anticipated product roll-out plans through the
remainder of the 2024 calendar year.
The Eons Deeper Sleep product is a rapid dissolve format that a
user places under their tongue sublingually. The Company’s
Quicksome™ technology enables the use of a fraction of the active
ingredients of competitive products in the nutraceutical space with
great effect, including rapid onset and reduced variability due to
substances diffusing directly into the bloodstream through tissues
under the tongue, bypassing the gastrointestinal tract where
substances absorbed in the intestines are subject to first-pass
metabolism in the liver before entering the general
circulation.
The efficacy of Eons Deeper Sleep product was tested internally
with oversight by the Company’s Director of Research and
Development, Richa Mandalay, to gauge the impact of a variety of
sleep measurements. The testing involved the use of a well-known
wearable device that tracks over 20 biometrics related to
well-being. Participants tracked their sleep biometrics for up to
45 days through the wearable technology, and documented instances
where the Deeper Sleep product was consumed prior to bedtime. One
hundred percent of participants experienced improved sleep scores
with the following key outcomes documented:
Total Sleep Average: Increased from
387.98 minutes to 450.17 minutes. REM Sleep Average:
Increased from 76.50 minutes to 97.22 minutes. Deep Sleep
Average: Increased from 73.81 minutes to 100.96 minutes.
Time Awake Average: Decreased from 74.77 minutes to 62.12
minutes.
“Seeing the results of the Deeper Sleep study was a validation
of the impact Quicksome™ can have in using high-quality ingredients
in a smaller dose than typical competitors are using,” continued
Hancock. “As we believe consumers are becoming more aware than ever
in what they are putting into their bodies, using less of an
ingredient to greater effect is a key part of the Quicksome™ value
proposition.”
MVMD has commenced its business development work with its Lead
Manufacturer, who has a broad list of clientele who currently
purchase “white label” and proprietary products from the Lead
Manufacturer. The Company has several proprietary formulation
projects with multiple business prospects, including, by way of
example, work with a biotech company in the USA that is working on
an opioid use disorder (OUD) solution. To date, the Company has
worked with its Lead Manufacturer on a proprietary OUD formulation
using the Company’s technology and samples have been created and
provided to the client for initial feedback, with the objective to
support their planned OUD clinical trials in the third calendar
quarter of 2024. The OUD clinical trials are being designed to
focus on helping patients with an adjunct therapy that helps to
reduce opioid cravings and increasing the instances of relapse
prevention.
To support anticipated business development initiatives planned
for the latter half of the 2024 calendar year, the Company has
completed Quicksome™ formulations for a broad product line,
including sleep, energy, appetite suppressant, pain relief, focus,
stress and anxiety relief.
AGRICULTURE
Agrarius Business Development and Product
Registration/Salability Advancements including Brazil, Colombia and
Canada
Following its year end, MVMD closed a transaction with Agrarius
Corp. (“AC”), whereby the Company executed an Amended and Restated
Supply and License Agreement with AC to acquire an exclusive
license to AC’s agricultural plant signaling technology in North
America, Mexico, South America, Central America, and the Caribbean
(the “Exclusive Territory”). The Agrarius product is certified
organic through the Organic Materials Review Institute (OMRI) in
the USA and is designed to be applied to agricultural crops to
naturally increase yields, reduce fertilizer usage, and increase
general resilience to pests and climate change.
The Agrarius product is mixed either with water or with other
agricultural products, such as fertilizers, pesticides, or
herbicides, at the point of application and then applied via
sprayer to agricultural crops at ideal times during a plant’s
lifecycle. Agrarius has been tested across numerous major
agricultural crops and has demonstrated its ability to naturally
increase crop yields from approximately ten to fifty percent or
more depending on crop type, reduce fertilizer usage where used by
more than thirty percent, and increase general resilience to pests
and climate change forces such as drought.
MVMD believes Agrarius presents a significant opportunity to
support its growth objectives given the rapidly changing global
agricultural landscape due to mass fertilizer shortages, population
growth, and urban sprawl limiting available farmlands and has
focused significant resources on the development of this line of
business.
The Company’s agronomists have been working with certified
third-party agricultural testing partners and academic institutions
to conduct extensive metabolic and physiological analysis studies
for Agrarius-treated crops to more closely evaluate the different
metabolic routes involved in plant stress responses, which include
enzyme regulation, chlorophyll production, and overall crop health
and yields compared to control plants, when fertilizers and
pesticides are systematically reduced and when other environmental
factors are involved, in numerous crop trials. The Company believes
the third-party reports received for the initial analysis, using
molecular biology techniques and chemical reduction studies for
fertilizer and pesticide usage, are very positive in support of the
numerous benefits to crops from Agrarius applications, including
enhancing overall plant health, increasing yields, and the
potential to actively reduce fertilizer and pesticide usage where
desired, while using the Agrarius product. The Company plans on
publishing this data in greater detail once a full analysis is
received and reviewed across various crop types.
MVMD is currently conducting business development activity in
Mexico, Central America, South America, Canada, and the United
States of America, within the Exclusive Territory. The Company has
been working with AC on the product registrations in key focus
markets in line with its business development activities and the
product is now officially saleable in all of the European Union, 44
states in the USA (with additional state approvals anticipated
through the 2024 calendar year), Canada, and Brazil. Additionally,
the Company received import approval for Colombia on July 19, 2024,
and anticipates the final government approval for Agrarius sales
inside Colombia by early August 2024. The Company anticipates
additional registration approvals through the remainder of the 2024
calendar year in Panama, Costa Rica, Peru, Uruguay, and Mexico, and
is working through a broader registration strategy to address
Agrarius salability through all of Central and South America in
line with anticipated demand.
“We believe the recent attainment of registration in Brazil is
significant to support our commercialization plans and long-term
shareholder value creation,” continued Hancock. “Brazil is one of
the largest agricultural markets in the world and we have a very
strong business development pipeline in this market that includes
directly working with some of the top agricultural organizations in
the world who have been introduced to Agrarius and are actively
trialing or planning trials with the Agrarius product.”
To support the positive registration developments and its
broader business development objectives, the Company has been
working to secure trademark protection for the Agrarius brand and
has filed initially for Agrarius trademark protection for Brazil,
Mexico, Chile, Colombia, Uruguay, Panama, Costa Rica, Peru,
Ecuador, Argentina, Paraguay, and Bolivia.
As part of the execution of the Amended and Restated Supply and
License Agreement with AC, the Company has launched a performance
guarantee program (the “Performance Guarantee Program”), initially
targeting farm operations in Canada and the United States, whereby
the Company’s prospective client is required to pay for the
Agrarius product only after it has achieved a minimum agreed
performance enhancement on the targeted crop. The Performance
Guarantee Program is designed to demonstrate the believed
disruptive nature of the Agrarius product, while limiting the risk
of any financial investment by the prospective client and ensuring
the desired outcome of yield improvement and increased plant health
are achieved in line with compensation.
Given the seasonality of the North American agricultural
industry and crop planting and harvest cycles, the allocated
Performance Guarantee Program inventory is being marketed to
potential clients for immediate application to eligible crops or by
way of purchase order commitments for early spring 2025 crop
applications. A goal of the program is to minimize trialing
cautiousness that the Company believes to be common with farmers
who may otherwise be hesitant to apply new agricultural products to
their crops without first trialing on smaller areas of their crops.
The Company has contracted with farming clients who have applied
Agrarius under the Performance Guarantee Program on crops that
include: corn, russet potatoes, faba beans, wheat, barley, and
canola. Given the first application of Agrarius is typically
applied early to crops when there are three to four leaves in the
growth cycle, there is very little time or target crops available
in North America for the current 2024 calendar year, resulting in
the Company anticipating the majority of the inventory that is
allocated to the Performance Guarantee Program to be secured
against purchase order commitments for applications in early spring
of the 2025 calendar year.
To support the Company’s business development objectives and
implementation of the Performance Guarantee Program, MVMD has
recently employed a global Agrarius brand update, including a focus
on developing internationalization into the website's strategy and
present market-specific content in the user’s native/preferred
language based on identifying IP address locale. This includes the
development of a primary Agrarius brand positioning video asset to
support business development in English, Spanish and Portuguese
languages.
Given the recent confirmation of Agrarius registration and
salability in Brazil, Canada, expanded USA states and the near-term
approval anticipated in Colombia, management believes that initial
Agrarius-related revenues can be expected in the fourth quarter of
the 2024 calendar year.
HUSBANDRY ANIMALS / AQUATIC SPECIES
Soluvec™ 1% Product Developments, First Product Shipments
Planned in Q3, 2024
The Company has applied its Quicksol™ solubilization technology
to the drug Ivermectin to create its Soluvec™ 1% product
formulation, which was designed to provide a safer and more
effective solution that can be administered broadly across the
husbandry animal and aquatic species marketplace. The Company has
demonstrated through a third-party Contract Research Organization
(CRO) that its Soluvec™ 1% is 2,500 times more soluble than
standard Ivermectin, enhancing its potential efficacy and its
ability to be absorbed across multiple applications.
The Company previously disclosed positive outcomes of multiple
pharmacokinetic trials that were conducted under the supervision of
The People's Republic of Bangladesh’s Ministry of Fisheries &
Livestock for an injectable Soluvec™ 1% solubilized Ivermectin
technology, and Soluvec™ 1% coated standard fish feed across farmed
fish species. In aquaculture, Soluvec™ 1% treated feed led to
enhanced growth and survivability outcomes in species like Indian
Catfish and Tilapia, indicating potentially substantial benefits
for biomass production.
Farmed fish trials were conducted on Indian Catfish, Pangas,
Common Carp, Tilapia, and Rui (Ruho) fish species. One group
received Soluvec™ 1% coated standard fish feed, while the control
group was given non-Soluvec™ 1% standard fish feed. The results
showed an increase in average daily growth and a reduction in
mortality, leading to an overall net average increase in net
production of 145%. The feed conversion ratio also improved by an
average of 16% for all fish species treated with Soluvec™ 1% coated
fish feed compared to those receiving non-Soluvec™ 1% coated fish
feed, indicating that the former group required less feed to
produce higher units of biomass.
The Company executed a license agreement with a privately held
Ontario corporation (the “Licensee”) for its Soluvec™ 1% animal
husbandry applications for the territory of the People's Republic
of Bangladesh. In exchange for a royalty percentage against net
sales, the agreement provides the Licensee with the exclusive
rights, within Bangladesh, to work through its partners inside the
territory to coordinate Soluvec™ 1% manufacturing and distribution
of related Soluvec™ 1% products, both in injectable and food
coating applications.
The Licensee has confirmed to management that it has received
necessary government approvals and completed the manufacturing
agreements that have enabled the Licensee to commence manufacturing
of the Soluvec™ 1% coated standard fish feed for farmed fish
species within Bangladesh. The Licensee had communicated to the
Company that it anticipated the salability of its Soluvec™ 1%
coated standard fish feed in Bangladesh in the second quarter of
the 2024 calendar year but is currently navigating start-up delays
from challenges sourcing initial raw material inventory needed for
manufacturing by approximately 60 days, and that have been
compounded by the recent cyclone Remal in May 2024 that affected
Bangladesh.
The Company was made aware by its Licensee that the recent
cyclone Remal that affected West Bengal and Bangladesh in May 2024
was devastating for the coastal fish farming sector. Floods
triggered by the storm have created severe damage to fish
enclosures, ponds, and related infrastructure, resulting in
substantial financial losses for Bangladesh fish farmers1.
Despite the delays communicated by the Licensee to the Company,
the Licensee has shared with management that the Licensee has
contracted with five distributors in Bangladesh and plans to
formally ship Soluvec™ 1% coated standard fish feed for farmed fish
species within Bangladesh in the third quarter to the 2024 calendar
year.
The Licensee has also communicated to the Company that the
Licensee is working on expanding production and sales focus to
broader husbandry applications across Bangladesh to support
expanded sales opportunities beyond the current aquatic species
focus.
The Company continues to evaluate the opportunity to license its
Soluvec™ 1% product in territories outside of Bangladesh. The
government product approval from Bangladesh granted to the Licensee
for farmed fisheries enables the Company to look at strategic
business development initiatives in line with the product
production capability in Bangladesh. The Company believes that
sending commercially manufactured samples of the Soluvec™ 1%
product will reduce costs and enable several independent evaluation
trials to happen simultaneously with potential key partners in a
variety of territories. The Licensee has communicated to the
Company that it has no restrictions on its export capacity from the
government of Bangladesh under its current sales and manufacturing
license.
To safeguard its intellectual property and the Company’s
licensing royalty model, the Company has initially filed for
Quicksol™ patent protection in key markets it has deemed
strategically important at this time for expansion outside of
Bangladesh. MVMD has filed for Soluvec™ protection in 12 additional
markets outside of the United States, including Canada, China,
India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil,
Peru, Argentina, and Chile.
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
Mountain Valley MD is building a world-class organization
centered around the implementation, licensing and reselling of key
technologies and formulations:
- patented Quicksome™ oral formulation and delivery
technologies
- patented Quicksol™ solubility formulation technology
- licensed product reseller of Agrarius™, a novel agricultural
plant signaling technology
Consistent with its vision towards “More Life”, MVMD applies its
owned and licensed technologies to its work for advanced delivery
of molecules for human and husbandry animal applications, including
the development of products for pain management, weight loss,
energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work
with Agrarius is focused on generating a positive impact on crop
yields and reducing fertilizer usage.
MVMD’s patented Quicksome™ technology utilizes proprietary
formulations and stabilizing molecules to encapsulate and formulate
active ingredients into highly efficient product formats. The
result is a new generation of product formulations that could be
capable of delivering nutraceutical and drug molecules into the
body faster, with greater impact, efficiency and accuracy.
MVMD’s patented Quicksol™ technology covers all highly
solubilized macrocyclic lactones that could be effectively applied
in multiple viral applications that could positively impact human
and animal health globally.
MVMD’s licensed Agrarius™ agricultural plant signalling
technology is designed to be applied to crops to naturally increase
yields, reduce fertilizer usage, and increase general resilience to
pests and climate change.
For more Company information and contact details, visit
www.MVMD.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION
Certain statements contained in this news release may constitute
forward-looking information. Forward-looking information is often,
but not always, identified by the use of words such as
"anticipate", "plan", "estimate", "expect", "may", "will",
"intend", "should", and similar expressions. Forward-looking
information involves known and unknown risks, uncertainties and
other factors that may cause actual results or events to differ
materially from those anticipated in such forward-looking
information.
The Company's actual results could differ materially from those
anticipated in this forward-looking information as a result of
regulatory decisions, competitive factors in the industries in
which the Company operates, prevailing economic conditions, and
other factors, many of which are beyond the control of the
Company.
The Company is making forward-looking statements, including but
not limited to: business development efforts in relation to each
line of business and new licensees and the timing thereof;
Circadian’s anticipated product roll-out plans and the timing
thereof; OUD clinical trials and the timing thereof; the proposed
impact of Agrarius on the Company and its growth objectives;
Agrarius analysis studies and the anticipated final results,
release and timing thereof; the attaining of additional
registrations for Agrarius, and the locations and timing thereof;
the Performance Guarantee Program, anticipated results thereof, and
anticipated timing related to additional trials and purchases;
anticipated timing for initial revenues from Agrarius; the timing
of commercialization of Soluvec™ 1% inside Bangladesh and matters
related thereto; and future opportunities for Soluvec™ 1% outside
of Bangladesh.
The Company believes that the expectations reflected in the
forward-looking information are reasonable, but no assurance can be
given that these expectations will prove to be correct and such
forward-looking information should not be unduly relied upon. Any
forward-looking information contained in this news release
represents the Company's expectations as of the date hereof and is
subject to change after such date. The Company disclaims any
intention or obligation to update or revise any forward-looking
information whether as a result of new information, future events
or otherwise, except as required by applicable securities
legislation.
Neither the CSE nor OTC has reviewed or approved the contents of
this press release.
1
https://seafoodnetworkbd.com/cyclone-remal-devastates-coastal-fish-farming-in-bangladesh
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240802216633/en/
For further information:
Dennis Hancock President and Chief Executive Officer Mountain
Valley MD Holdings Inc. Investor Relations @ 647-725-9755 Email:
info@mvmd.com www.MVMD.com
Grafico Azioni Mountain Valley MD (TG:20MP)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Mountain Valley MD (TG:20MP)
Storico
Da Dic 2023 a Dic 2024
